NDA for Investigational Rosacea Treatment Submitted to FDA

Foamix Pharmaceuticals has submitted a New Drug Application (NDA) for FMX103, an investigational treatment for moderate to severe papulopustular rosacea in patients ≥18 years old. FMX103 is a topical foam formulation of minocycline. The NDA submission includes data from two phase 3 trials in which the efficacy and safety of the minocycline foam 1.5% was…

Sustained Use of Oxymetazoline Cream Efficacious for Rosacea

The researchers found that 8.2% of patients reported treatment-emergent adverse events (TEAEs), the most common were application site dermatitis, paresthesia, pain, and pruritus. Several authors disclosed financial ties to Allergan, which is a manufacturer of oxymetazoline.